Insulin NovoNordisk Levemir 100 E/ml FlexPen

Insulin NovoNordisk Levemir 100 E/ml FlexPen is a medicine authorised by Swissmedic under authorisation number 56371. The authorisation holder is Novo Nordisk Pharma AG. The medicinal product code is Biotechnological medicines and the dispensing category is B: Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly. First authorisation was granted on 10 November 2003 and the authorisation is limited until 31 March 2027. ATC code A10AE05 places the medicine in the group Drugs used in diabetes.

  • Dispensing category B
  • Authorisation number 56371
  • ATC A10AE05
  • Biotechnological medicines
Authorisation data
Authorisation number56371
NameInsulin NovoNordisk Levemir 100 E/ml FlexPen
Full nameInsulin NovoNordisk Levemir 100 E/ml FlexPen, Injektionslösung
Authorisation holderNovo Nordisk Pharma AG
Medicinal product codeBiotechnological medicines
Dispensing categoryB · Prescription only
ATC codeA10AE05
First authorisation10 November 2003
Authorisation validity31 March 2027
Strengths
No.NameDispensing categoryAuthorisation date
2Insulin NovoNordisk Levemir 100 E/ml FlexPen, InjektionslösungB30 April 2009

Scroll the table sideways

Pack sizes
Pack codeQuantityUnitATCIT codeDispensing category
35 x 3mlA10AE0507.06.1.B

Scroll the table sideways

Medicines in the same ATC group

Other medicines from this authorisation holder

Frequently asked questions

Is Insulin NovoNordisk Levemir 100 E/ml FlexPen authorised in Switzerland?

Yes. Insulin NovoNordisk Levemir 100 E/ml FlexPen is authorised by Swissmedic under authorisation number 56371, data as of 01 September 2026. The authorisation is limited until 31 March 2027.

Which dispensing category does Insulin NovoNordisk Levemir 100 E/ml FlexPen have?

Insulin NovoNordisk Levemir 100 E/ml FlexPen is in dispensing category B. Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly.

Who is the authorisation holder of Insulin NovoNordisk Levemir 100 E/ml FlexPen?

The authorisation holder is Novo Nordisk Pharma AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.

Sources

Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.

Authorisation in Switzerland?

About 2 minutes. No obligation.

First, a little about your business.

Your answers stay in this page until you send your enquiry.

What would you like to achieve?

Your project

Where can we reach you?

You can go back to review your answers before sending.

* Required fields
Prefer email? info@swissmedicinesdirectory.com